Want to see AU:VLS full AI Analyst Report?
VLS Stock Chart & Stats
AU$2.52
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.52
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$2.15 - AU$2.84
Previous CloseN/A
Volume18.65K
Average Volume (3M)14.76K
Market Cap
AU$132.67M
Enterprise ValueAU$98.07M
Total Cash (Recent Filing)AU$35.56M
Total Debt (Recent Filing)AU$2.39M
Price to Earnings (P/E)13.1
Beta-0.06
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.53%
Share Statistics
EPS (TTM)0.19
Shares Outstanding54,371,357
10 Day Avg. Volume12,408
30 Day Avg. Volume14,758
Financial Highlights & Ratios
PEG Ratio0.72
Price to Book (P/B)2.57
Price to Sales (P/S)1.55
P/FCF Ratio9.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Steady Multi-year Revenue GrowthSustained revenue growth over multiple years indicates durable demand for VLS's branded VMS products and successful distribution/marketing execution. This revenue scale supports investment in product development, distribution reach and provides a foundation for long-term earnings expansion and operational leverage.
Healthy Margin StructureConsistently high gross margins and double-digit net margins show the business has structural pricing power or favorable product mix in the VMS category. Strong margins support cash generation, buffer cost inflation, and make the business resilient to competitive pressure while enabling reinvestment and shareholder returns.
Conservative Balance SheetVery low leverage and steadily growing equity provide financial flexibility and downside protection. This conservative capital structure allows VLS to fund growth, withstand demand shocks, pursue opportunistic M&A or return capital, all of which enhance long-term durability of the business model.
Bears Say
Margin Compression TrendA multi-year decline in margins suggests rising cost pressure, increased promotional activity, or less favorable product mix as the business scales. If persistent, this reduces the company's ability to convert revenue into earnings and limits free cash flow available for reinvestment or dividends over the medium term.
Volatile Cash Flow ConversionIrregular conversion of profit to free cash flow signals working-capital swings or timing mismatches with receivables/inventory. This unpredictability can constrain reliable investment planning, dividend sustainability and may force precautionary liquidity buffers that reduce capital efficiency.
Diminishing Returns On Incremental CapitalFalling returns on capital from prior peaks indicate the business may be facing tougher competitive dynamics or diminishing high-return expansion opportunities. Over time this can limit ROE improvement and make additional investment less accretive for shareholders unless offset by new product or market breakthroughs.
Vita Life Sciences Limited News
VLS FAQ
What was Vita Life Sciences Limited’s price range in the past 12 months?
Vita Life Sciences Limited lowest share price was AU$2.15 and its highest was AU$2.84 in the past 12 months.
What is Vita Life Sciences Limited’s market cap?
Vita Life Sciences Limited’s market cap is AU$132.67M.
When is Vita Life Sciences Limited’s upcoming earnings report date?
Vita Life Sciences Limited’s upcoming earnings report date is Aug 20, 2026 which is in 12 days.
How were Vita Life Sciences Limited’s earnings last quarter?
Vita Life Sciences Limited released its earnings results on Feb 16, 2026. The company reported AU$0.1 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.1.
Is Vita Life Sciences Limited overvalued?
According to Wall Street analysts Vita Life Sciences Limited’s price is currently Overvalued.
Does Vita Life Sciences Limited pay dividends?
Vita Life Sciences Limited pays a Semiannually dividend of AU$0.095 which represents an annual dividend yield of 5.53%. See more information on Vita Life Sciences Limited dividends here
What is Vita Life Sciences Limited’s EPS estimate?
Vita Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vita Life Sciences Limited have?
Vita Life Sciences Limited has 54,371,357 shares outstanding.
What happened to Vita Life Sciences Limited’s price movement after its last earnings report?
Vita Life Sciences Limited reported an EPS of AU$0.1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.958%.
Which hedge fund is a major shareholder of Vita Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:VLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vita Life Sciences Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:VLS Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth AU$230.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.60%
12-Months-Change
Fundamentals
Return on Equity
5.53%
Trailing 12-Months
Asset Growth
14.56%
Trailing 12-Months
Company Description
Vita Life Sciences Limited
Vita Life Sciences Limited is an Australian healthcare company specializing in the formulation, packaging, distribution, and sale of vitamins and nutritional supplements. The company's reach spans Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. In addition to core supplements, their product range encompasses minerals, various herbs, and superfoods. They offer solutions targeting a broad spectrum of therapeutic areas, including nervous system support, general nutrition, immunity, hair, skin, and nails, liver and digestion, weight management, cardiovascular health, pain and inflammation, pregnancy and breastfeeding, and health specifically for men, women, and children. Products also provide antioxidant benefits and support for bones and joints. Marketed under their prominent brands—Herbs of Gold, VitaHealth, and VitaScience—these offerings are sold through pharmacies and health food channels. Established in 1947, Vita Life Sciences Limited is headquartered in Kirrawee, Australia.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Epsilon Healthcare Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―